The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. Currently, the antibiotic resistance is one of the world’s most pressing public health problems. It is estimated that about 33,000 people die every year in the EU/EEA as a direct consequence of an infection due to bacteria resistance to antibiotics. Moreover, it is found that around 70% of all antibiotics administered are used for animals. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or light-emitting diode (LED), are less efficient, given their cost, unpleasant feeling, treatment-time and required area.
Therefore, neoplas GmbH has successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals (e.g. milk cows, horses, cats, dogs). It stimulates and accelerates physiological wound healing and it is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. In addition, in the course of increasing the fight against antibiotic resistance, the chances for kINPen®VET as alternative wound treatment are good for a successful market introduction.
With the support of the European commission kINPen®VET is able to accelerate the upscaling and to keep R&D and pilot line activities on high level to further upgrade the system quality and to develop more technological research about cold plasma. Moreover, kINPen®VET is a great chance to extend the Europe- and worldwide contacts to potential customers. It is important to highlight that kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country.
